Daily digital memory chats for people with mild memory and thinking problems
Observes daily app-based memory sessions and their link to apathy and low mood.
Key facts
- Who runs it
- KompanionCare SAS
- Where
- France5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 14 Oct 2025
- Expected to end
- Dec 2026
- Type of study
- Observational
- Record updated
- 9 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 60 with mild memory and thinking problems, who also have mild or moderate low mood or lack of motivation. They will use a personal memory-sharing app daily for 25 days.
- Age
- Over 60 years
- Sex
- Men and women
- Disease stage
- Early stage of major neurocognitive disorder or mild cognitive impairment (MCI), any cause, with an MMSE score from 21 to 28. Mild or moderate depression, mild or moderate apathy, or both.
- Earlier treatment
- No new medicine for neurocognitive disorders in the 3 months before the inclusion visit. No earlier use of the Lilia app.
Main reasons for not taking part
- Moderate or severe dementia (MMSE score 20 or lower)
- Major psychiatric illness, such as schizophrenia, severe major depression or bipolar disorder
- Major hearing or vision problems
- Intellectual disability from before the illness
- Being under guardianship, conservatorship or legal protection
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Men and women over 60 years of age
- DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes
- Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28
- Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both
- Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool
- Having voluntarily and informedly agreed to participate in the study (signed written consent)
- Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool)
- Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access
- Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group
- Subjects covered by a social security scheme
Who cannot take part
- Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit
- Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD
- Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder)
- History of premorbid intellectual disability
- Major hearing or visual impairments
- Patients under guardianship, conservatorship, or legal protection
- Patients who have already used the Lilia app
- Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.
Read full original descriptionShow less
The researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.
The study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.
Participants will:
* Use the reminiscence app for 25 days for 10-15 minutes. * Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group. * Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).
The group in the trial
- DRT Users
Single observational cohort exposed to a personalized digital reminiscence therapy, through daily 10-15 minute sessions.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders
- Plain-language title
- Daily digital memory chats for people with mild memory and thinking problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 9 March 2026